Previous studies have demonstrated that CHEK2 c.1100del heterozygotes have a two-fold risk of malignant melanoma compared to non-carriers, while no clear associations have emerged between Mullerian sarcomas or, more generally, isolated uterine tumors and CHEK2 [71,72]. Here, CHEK2 is linked to melanoma.